CRSP-6.90%14.0%
NTLA-3.52%13.0%
BEAM+47.92%11.0%
PRME-24.32%9.0%
VERV0.00%8.0%
CRBU-14.36%6.0%
RCKT+15.89%6.0%
EDIT+8.70%5.0%
MGX-42.14%5.0%
SGMO0.00%5.0%
SRPT-2.03%5.0%
QURE+227.95%4.0%
RGNX+27.58%4.0%
FDMT+79.41%3.0%
MGTX+57.86%2.0%
As of Aug 6, 2026, 4:25 AM ET
Genomics '25: Gene Editing & Genetic Meds Constituents
CRISPR Therapeutics AGCRSP | 14.0% | -1.17% | 12.70% | -15.25% | 9.29% | 0.02% | -12.79% | 53.41% | -6.90% | $5.06B |
Intellia Therapeutics, Inc.NTLA | 13.0% | -3.09% | 2.24% | -38.51% | 2.72% | 22.02% | -20.39% | 50.27% | -3.52% | $1.23B |
Beam Therapeutics Inc.BEAM | 11.0% | -4.51% | 7.85% | -23.36% | 6.07% | -2.34% | -4.88% | 46.48% | 47.92% | $2.78B |
Prime Medicine, Inc.PRME | 9.0% | 3.36% | 4.41% | -22.81% | 5.48% | -11.24% | -33.33% | 72.07% | -24.32% | $556.3M |
Verve Therapeutics, Inc.VERV | 8.0% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 60.36% | 0.00% | $560.0M |
Caribou Biosciences, Inc.CRBU | 6.0% | 2.55% | 2.55% | -12.02% | 10.27% | 1.26% | -15.26% | 86.99% | -14.36% | $159.7M |
Rocket Pharmaceuticals, Inc.RCKT | 6.0% | 1.74% | 9.72% | -12.28% | 12.54% | -0.28% | -30.14% | -44.44% | 15.89% | $382.2M |
Editas Medicine, Inc.EDIT | 5.0% | -0.72% | 5.77% | -24.66% | 6.59% | 34.15% | 25.00% | 133.05% | 8.70% | $269.2M |
Metagenomi, Inc. Common StockMGX | 5.0% | 0.41% | 0.83% | -2.80% | 2.10% | -25.00% | -20.07% | -8.65% | -42.14% | $45.7M |
Sangamo Therapeutics, Inc.SGMO | 5.0% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | $1.80B |
Sarepta Therapeutics, Inc.SRPT | 5.0% | -2.81% | 1.59% | -16.94% | 7.20% | -25.98% | -4.95% | -74.50% | -2.03% | $1.68B |
REGENXBIO Inc.RGNX | 4.0% | 1.94% | 7.91% | -29.20% | 8.36% | -27.08% | 16.15% | 48.94% | 27.58% | $542.8M |
uniQure N.V.QURE | 4.0% | 1.28% | 13.52% | 6.96% | 1.40% | 84.87% | 183.05% | 316.57% | 227.95% | $3.07B |
4D Molecular Therapeutics, Inc.FDMT | 3.0% | 0.19% | 2.09% | -19.18% | 0.98% | 37.07% | 6.42% | 213.41% | 79.41% | $537.4M |
MeiraGTx Holdings plcMGTX | 2.0% | 2.12% | 6.63% | -9.65% | 6.45% | 57.86% | 66.01% | 97.33% | 57.86% | $1.16B |
| Theme return | — | -0.48% | 5.53% | -16.06% | 5.52% | 11.72% | -0.86% | 80.41% | 19.22% | — |
| Average | 6.7% | 0.09% | 5.19% | -14.65% | 5.30% | 9.69% | 10.32% | 70.09% | 24.80% | $1.32B |
| Median | 5.0% | 0.19% | 4.41% | -15.25% | 6.07% | 0.00% | -4.88% | 53.41% | 0.00% | $560.0M |
| Std Dev | 3.5% | 2.17% | 4.28% | 11.90% | 3.80% | 30.91% | 51.95% | 94.23% | 62.40% | $1.34B |
| Min | 2.0% | -4.51% | 0.00% | -38.51% | 0.00% | -27.08% | -33.33% | -74.50% | -42.14% | $45.7M |
| Max | 14.0% | 3.36% | 13.52% | 6.96% | 12.54% | 84.87% | 183.05% | 316.57% | 227.95% | $5.06B |
| % Positive Tickers | 53.33% | 86.67% | 6.67% | 86.67% | 46.67% | 33.33% | 73.33% | 46.67% |
Default: Wgt ↓ · Click headers to sort · Shift+click secondary
About this theme
Genomics '25: Gene Editing & Genetic Meds tracks 15 publicly listed stocks in this theme. Sample tickers: BEAM, CRBU, CRSP, EDIT, FDMT, MGTX, MGX, NTLA, PRME, QURE, RCKT, RGNX, and 3 more. Use the table below for the full list.